Intellectual Product

HHS Issues Guidance to Shield Pharma from Anti-Kickback Violations in TrumpRx Direct-to-Consumer Drug Sales

3 days ago talkbio0Tagged Anti-Kickback Statute (, CHARGE Syndrome, Direct-to-Consumer, Drug Prescriptions, OIG bulletin, TrumpRx

TrumpRx; HHS; anti-kickback statute; direct-to-consumer; prescription drugs; OIG bulletin

SBA Defends 8(a) Program Reforms Amid Constitutional Challenges and Increased Scrutiny in 2026

5 days ago talkbio0Tagged 8(a, business practices, Constitutional Challenges, Programs - Publication Format, SBA, social disadvantage, Trump administration

8(a) program; SBA; business practices; constitutional challenges; Trump Administration; social disadvantage

J&J Brushes Off MFN Impact, Forecasts $100 Billion Revenue Milestone for 2026

2 weeks ago talkbio0Tagged Innovative Medicine, J&J, Johnson & Johnson, medtech, MFN, Projections and Predictions, Trump drug pricing

J&J; Johnson & Johnson; MFN; Trump drug pricing; 2026 forecast; $100 billion; MedTech; Innovative Medicine

Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support

2 weeks ago talkbio0Tagged AI health, Ant Afu, Ant Group, Autism Spectrum Quotient, Clinical Decision Support, DeepSearch, evidence-based, PC Platform

Ant Group; AQ; Ant Afu; DeepSearch; PC platform; evidence-based; clinical decision support; AI health

Trump Unveils ‘The Great Healthcare Plan’ to Lower Drug Prices and Target Insurers

2 weeks ago talkbio0Tagged drug price, Great Healthcare Plan, Health Care Reform, Insurance Premiums, price transparency, Transplant Registry Unified Management Program

Trump; Great Healthcare Plan; drug pricing; insurance premiums; price transparency; healthcare reform

Eikon Therapeutics Files for IPO Amid Biotech Rally Test

3 weeks ago talkbio0Tagged cancer drugs, Eikon, File (record), IPO, Nasdaq EIKN, rally

Eikon Therapeutics; IPO filing; biotech rally; cancer drugs; Nasdaq EIKN

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

3 weeks ago talkbio0Tagged AI-driven, biotherapeutics, Country, developability, Drug Kinetics, Evotec SE, Financial cost, funding grant, Gates Foundation * *, Global Health, HIV, Immunogenicity (package insert), J.MD, low, Malaria, manufacturability, Manufactured Supplies, middle-income, Monoclonal Antibodies, Optimization, Platform, Respiratory syncytial virus, Stable status, Titer

Evotec SE; Gates Foundation; grant; J.MD; J.DESIGN platform; AI-driven optimization; monoclonal antibodies; biotherapeutics; developability; manufacturability; stability; immunogenicity; pharmacokinetics; titer; cost of goods; global health; affordable access; low- and middle-income countries; RSV; malaria; HIV

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions